Intravesical Gene Therapy for BCG Refractory Bladder Cancer

$203,200P50FY2012CANIH

University Of Tx Md Anderson Can Ctr, Houston TX

Investigators

William Francis Benedictcontact Colin P Dinney

Linked publications & trials

Paper 38676926 Paper 37442564 Paper 37246493 Paper 36404232 Paper 35770498 Paper 34920986 Paper 34184926 Paper 33935020 Paper 33881933 Paper 33783950 Paper 33563539 Paper 33502236 Paper 33258948 Paper 32546765 Paper 32253420 Paper 32122956 Paper 31757304 Paper 31067463 Paper 30415317 Paper 29955780 Paper 29763719 Paper 29660813 Paper 29529165 Paper 29428551 Paper 29235103 Paper 29179475 Paper 29174465 Paper 29088836 Paper 28988769 Paper 28851898 Paper 28834453 Paper 28827100 Paper 28826932 Paper 28823575 Paper 28753816 Paper 28365159 Paper 28149933 Paper 28102366 Paper 28018013 Paper 27845906 Paper 27825764 Paper 27818773 Paper 27797838 Paper 27612592 Paper 27499906 Paper 27494900 Paper 27480598 Paper 27387678 Paper 27291797 Paper 26988609 Paper 26922408 Paper 26907529 Paper 26732427 Paper 26515115 Paper 26464424 Paper 26364859 Paper 26343003 Paper 26280620 Paper 26173102 Paper 26119560 Paper 26032953 Paper 25896234 Paper 25851338 Paper 25443274 Paper 25416716 Paper 25320178 Paper 25219851 Paper 25199718 Paper 25027329 Paper 24931270 Paper 24525232 Paper 24503570 Paper 24449888 Paper 24391818 Paper 24163127 Paper 24121789 Paper 24053608 Paper 23946494 Paper 23911605 Paper 23874968 Paper 23657946 Paper 23553206 Paper 23529717 Paper 23507396 Paper 23500642 Paper 23468956 Paper 23322153 Paper 23284679 Paper 23272234 Paper 23251617 Paper 23239884 Paper 23040072 Paper 22914978 Paper 22895070 Paper 22879988 Paper 22863868 Paper 22742565 Paper 22701660 Paper 22586063 Paper 22583635

Abstract

The overall goal of these studies is to improve the treatment of non-muscle invasive bladder cancer by identifying second line agents that are effective in the scenario of BCG resistance and hopefully for all nonmuscle invasive bladder cancer in future years. During the course of the last cycle of SPORE funding, we provided strong evidence for effective gene transfer and potential clinical efficacy when intravesical adenoviral-mediated interferona(IFNa) gene therapy was administered with Syn3 (Ad-IFNa/Syn3). Approximately 50% of the treated patients, all of which were BCG resistant, obtained a complete remission (CR). We also found that Ad-IFNa induces cancer cell death in human bladder cancer cells that are insensitive to the recombinant IFNa protein itself, and that cell death occurs via direct and indirect (bystander) mechanisms. Moreover, normal urothelial cells appear to be resistant to Ad-IFNa. In this renewal we plan to complete a Phase IB study of intravesical Ad-IFNa/Syn3 to optimize the schedule by determining whether therapy on Day 1 and an additional instillation on Day 4 will enhance gene transfer and result in higher and more sustained urine IFNa levels than were achieved with a single treatment In patients achieving a CR at 90 days we will repeat treatment on Day 1 and 4 to determine whether redosing with this schedule will provide for effective gene transfer. TRAIL, M30 and M65 levels will also be measured in the urine as possible markers of clinical efficacy and tumor cell death. Subsequently we plan to participate in and lead a multicenter Phase II trial based upon the results of Phase IB study. The isolation and identification of the soluble factor(s) responsible for the Ad-IFNa produced bystander cell death on cancer cells will also be a focus. In addition to its obvious value as a biomarker of Ad-IFN activity, the bystander factor(s) could itself have clinical utility. Various methods will be utilized in these studies, including size exclusion concentration, size-exclusion FPLC column subfractionation and mass spectroscopy.

View original record on NIH RePORTER →